IMMUNOHISTOCHEMICAL EXPRESSION OF BETA CATENIN IN THYROID TUMORS – A PROSPECTIVE STUDY

Dr. S. Gurusamy, Dr. S. Vijayalakshmi

Abstract


Aim and objectives:

To evaluate the expression of beta-catenin in well differentiated and poorly / undifferentiated thyroid tumors. Also to identify tumors which may not have favourable outcome.

Methods :

In this study , paraffin blocks from 30 thyroidectomy specimens are stained  with monoclonal antibodies reactive with beta-catenin. These include

22 cases of papillary carcinoma of thyroid (PTC) ( 16 cases of conventional  PTC,  3 cases of Follicular variant, 2 cases of cribriform morular variant , 1 case of hobnail variant),

4 cases of Follicular carcinoma(FC),

3 cases of Medullary carcinoma (MC) and

1 case of Poorly differentiated carcinoma (PDC)

Results :

Papillary carcinoma conventional type, other variants of PTC and FC express residual membranous positivity and diffuse cytoplasmic positivity with occasional nuclear positivity. PTC,FVPC and hobnail variant show few nuclear inclusion positivity. PDC shows diffuse cytoplasmic positivity with severe loss of membrane positivity

Conclusion:

Loss of  membrane positivity of beta catenin with cytoplasmic and nuclear  expression correlates well  with aggressive behaviour i.e increased invasiveness and metastasis.


Keywords


PTC- Papillary carcinoma of thyroid, FVTC- Follicular variant of papillary carcinoma of thyroid, FC- follicular carcinoma, MC-medullary carcinoma, PDC- Poorly differentiated carcinoma,Beta-catenin

Full Text:

PDF

References


McNicol AM, Lewis PD . The endocrine system. In: LewisPD (ed) Systemic pathology. Churchill Livingstone, Edinburgh;1999. pp 131-182.

Doniah I. The thyroid gland. In:SymmersWStc (ed.) Systemic pathology , vol 4, 2nedn. Edinburgh: Churchill Livingstone; 1978:1975-2037

Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005.Cancer. 2009 Aug 15;115(16):3801-7

Bohm J, Niskanen L, Kiraly K, et al. Expression and prognostic value of alpha-, beta- and gamma-catenins in differentiated thyroid carcinoma. J ClinEndocrinolMetab .2005 May;85(12):4806–4811

Xu B, Yoshimoto K, Miyauchi A et al. Cribriformmorular variant of papillary thyroid carcinoma: a pathological and molecular genetic study with evidence

Rezk S, Brynes RK, Nelson V, Thein M, Patwardhan N, Fischer A, Khan A. beta-Catenin expression in thyroid follicular lesions: potential role in nuclear envelope changes in papillary carcinomas. EndocrPathol. 2004 Winter;15(4):329-37.

Sethi K, Sarkar S, Das S, Rajput S, Mazumder A, Roy B, Patra S, MohantyB,El-Naggar AK, Mandal M. Expressions of CK-19, NF-kappaB, E-cadherin, beta-cateninand EGFR as diagnostic and prognostic markers by immunohistochemical analysis in thyroid carcinoma. J ExpTherOncol. 2011;9(3):187-99.

National Cancer Institute Jul 6, 2018 Incidence and Types of Thyroid Cancer

Papillary, Follicular, Medullary, and Anaplastic Thyroid Cancers

Written by Bridget Brady MD, FACS

Jung C K, Choi Y J, Lee K Y et al. The cytological, clinical, and pathological features of the cribriform-morular variant of papillary thyroid carcinoma and mutation analysis of CTNNB1 and BRAF genes. Thyroid .2009;19: 905-913

Rossi ED, Straccia P, Palumbo M, et al. Diagnostic and prognostic role of HBME-1, galectin-3, and b-catenin in poorly differentiated and anaplastic thyroid carcinomas. ApplImmunohistochem MolMorphol. 2013;21(3):237–241.

Sethi K, Sarkar S, Das S, Rajput S, Mazumder A, Roy B, Patra S, MohantyB,El-Naggar AK, Mandal M. Expressions of CK-19, NF-kappaB, E-cadherin, beta-cateninand EGFR as diagnostic and prognostic markers by immunohistochemical analysis in thyroid carcinoma. J ExpTherOncol. 2011;9(3):187-99.

Tallini G. Molecular pathobiology of thyroid

neoplasms.Endocr Pathol.2002; 13:271–288

Ishigaki K, Namba H, Nakashima M, et al. Aberrant

localization of betacatenin correlates with overexpression of its

target gene in human papillary thyroid cancer. J

ClinEndocrinolMetab. 2002;87(7):3433–3440.

Rosai J, Saxen E A, Woolner L .Undifferentiated and poorly

differentiated carcinoma. SeminDiagnPathol.1985 May;2(2):

-126.

FábioMuradásGirard ,MarinezBizarro Barra , Cláudio Galleano

Zettler. Variants of papillary thyroid carcinoma: association

with histopathological prognostic factors .Braz J

Otorhinolaryngol. 2013;79(6):738-44.

Rosai J, Saxen E A, Woolner L .Undifferentiated and poorly

differentiated carcinoma. SeminDiagnPathol.1985 May;2(2):

-126.

Akslen L A, LiVolsi V A. Prognostic significance of histologic

grading compared with subclassification of papillary thyroid

carcinoma. Cancer.2000 Apr;88 (8 ): 1902-1908

Jung C K, Choi Y J, Lee K Y et al. The cytological, clinical, and pathological features of the cribriform-morular variant of papillary thyroid carcinoma and mutation analysis of CTNNB1 and BRAF genes. Thyroid .2009;19: 905-913


Refbacks

  • There are currently no refbacks.